CX : Customer Experience—the Customer Experience (CX) practice sits at the intersection of Design and Strategy at the agency.
Alexza Pharmaceuticals (Corporate, Staccato OBT) Aspen Green (Corporate)
Biofrontera (Ameluz, Xepi) Depuy Synthes Joint Reconstruction (Attune, Corporate, VELYS Digital Surgery, Kincise , Anterior Advantage Hospital Marketing, VELYS Robot, VELYS Hip Navigation, VELYS Patient Path, VELYS Insights, New BioMaterial for Orthpaedics, Johnson & Johnson Institute) DePuy Synthes Trauma (ASC Capabilities, Continuous Compression Implants, FIBULINK, Foot & Ankle, MAXFRAME Autostrut, Plates & Screws, Radial Head Replacement System, Universal Small Fragment System, Upper Extremities Franchise) Mitek Sports Medicine (MONOVISC, PEAK PRP System, ORTHOVISC) EyePoint Pharmaceuticals (DEXYCU, YUTIQ) Eyevance Pharmaceuticals (Flarex, TobraDex ST, Zerviate) Foundation Fighting Blindness (Corporate) Galen US (SYNERA) Grifols (Hypermunes, HyperRAB, Td Vax) Joerns Healthcare (Corporate, Connexio) Johnson & Johnson (Lung Cancer Initiative) LivaNova (VNS Therapy) Medexus USA (Rasuvo , Treosulfan) Mycovia Pharmaceuticals (Corporate, New Product Launch) NORD (Corporate) Recordati Rare Disease (Signifor LAR, Isturisa) Sentynl Therapeutics (Corporate, New Product Launch) Shield Therapeutics (Accrufer) Thea Pharmaceuticals (Corporate, New Product Launch)
2021 Growth from Existing Clients
2021 Growth from New Clients
Trends and Challenges
Diversity and inclusionTalent acquisition/retentionManaging growthGetting an audience, virtually or otherwise, with HCPsKeeping up with pace of innovationProcurement-related issuesShrinking pharma budgetsFurther diversification of servicesRegulatory concernsPandemic-related disruptions
Healthcare Marketing Trends
More personalization of communicationsNeed to create more/better content/experiencesHeightened focus on payersIncreased concern over drug pricingIndustry consolidationScrutiny around social mediaImpact of empowered patients/consumersIntensified focus on analytics/ROI/measurementDecreased impact of sales forcesRegulatory changesPrograms that go “beyond the pill”Evolution of EHRsEmphasis on specialty drugs/high-science categoriesAdopting a data-science cultureMore digital experimentationSeizing opportunities around cannabisWorking from homeOngoing fallout from pandemic
How condition-specific audience segments can lift your brand beyond traditional targeting.
Mapping the identity experience in digital health communications
How IX offers greater nuance in engaging with audiences.
The state of DE&I: Moving the needle from commitment to progress
Employees and consumers alike expect companies to take meaningful steps toward creating a more equitable and inclusive future. As shown by the findings from MM+M’s 2022 Diversity Survey, conducted in partnership with IPG Health, progress has been made but we still have a long way to go in the healthcare industry.
How to keep digital pharma marketing relevant in the times of global crises
Nataliya Andreychuk, CEO of Viseven, discusses digital marketing trends and more during her chat with Marc Iskowitz, editor-at-large, MM+M.